Starpharma adds to STI inhibition
Thursday, 04 December, 2008
The main ingredient in Melbourne biotech Starpharma’s developmental microbicide has shown activity in vivo against human papillomavirus 16 and 18, the company said.
These two strains of HPV are responsible for the vast majority of cervical cancers. Starpharma is developing a topically applied microbicide called VivaGel to reduce the risk of infection by several sexually transmitted diseases, including HPV, genital herpes and HIV.
The company said pre-clinical trials had shown the active ingredient, SPL7013, showed activity against HPV 16 and 18, in addition to previously shown activity against HPV 6 and 11, which cause genital warts.
The compound also demonstrated activity against two other minor strains of HPV that are thought to cause a low rate of cervical cancer but are not covered by the available cervical cancer vaccines.
Retinal health linked to dementia risk, study shows
Researchers have discovered that the blood vessels at the back of the eye — called retinal...
Pancreatic cancer hijacks metabolism switch to help it spread
Pancreatic cancer hijacks a molecule known for regulating physiological processes, such as food...
Novel antibiotic activates 'suicide' mechanism in superbug
Researchers have discovered a new class of antibiotic that selectively targets Neisseria...
